GALNT2

Across TCGA pan-cancer cohorts, GALNT2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GALNT2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GALNT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GALNT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LSCC, CCRCC, and HNSC are the cancer types where GALNT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.673	0.943	<.001	47	view →
CCRCC	OS	Median	All	0.725	0.932	<.001	46	view →
HNSC	DFS	Median	All	0.698	1.000	.020	20	view →
GBM	DFS	Tertile	All	0.249	0.508	<.001	14	view →
PDAC	DFS	Quartile	II,III,IV	0.252	0.460	.008	13	view →
UCEC	OS	Median	All	0.964	0.841	.016	6	view →
LUAD	OS	Median	II,III,IV	0.461	0.754	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GALNT2–LSCC (OS)

Open the LSCC breakdown →